Actavis Testosterone Drug Flouts 6 Patents, Eli Lilly Says

Law360, New York (November 14, 2013, 3:19 PM EST) -- Eli Lilly & Co. hit generic drugmaker Actavis Inc. and its subsidiaries with a suit Tuesday in Indiana federal court claiming that the company infringed six patents covering Eli Lilly's Axiron, a topical treatment used by men afflicted with low testosterone.

The complaint targets an abbreviated new drug application filed with the U.S. Food and Drug Administration detailing the plans of Actavis and a pair of its subsidiaries to manufacture and market a generic version of Axiron before the expiration of six Eli Lilly patents on...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.